Get started
Author

Olivier Arsène

Observed names: Arsene, Olivier, Arsène, Olivier, O Arsene, O Arsène, O. Arsene, O. Arsène, Olivier ARSENE, Olivier Arsene, arsene, olivier
Observed institutions: Hôpital Necker-Enfants Malades, Université de Toulon, Aix-Marseille Université, Sorbonne Paris Cité, Centre Hospitalier de Béziers, Centre Hospitalier Universitaire de Tours, Assistance Publique – Hôpitaux de Paris, Institut de Cancérologie de Lorraine, Hôpital Bretonneau, Centre Léon Bérard, Centre François Baclesse, Centre Hospitalier de Fougères, Centre Oscar Lambret, Institut Bergonié, Centre Hospitalier d'Arras, Hôpital Saint-Louis, Swiss Group For Clinical Cancer Research, Centre Hospitalier des Pays de Morlaix, Institut Jean Godinot, Institut des Maladies Génétiques Imagine, Université Paris Descartes, Centre d'Etudes et de Recherche en Gestion d'Aix-Marseille, Grenoble Ecole de Management, Institut Curie
ORCID: 0009-0002-0245-8114
Observed ORCID: 0009-0002-0245-8114
OpenAlex ID: A5026269617
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
2017 · Caroline Charlier, Élodie Perrodeau, et al. · The Lancet Infectious Diseases · 611
PDF
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · The Lancet Oncology · 404
PDF
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 179
PDF
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 133
PDF
Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
2019 · Elisé G. Kaboré, Charles Guenancia, et al. · PLoS Medicine · 78
PDF
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 31
Body weight and return to work among survivors of early-stage breast cancer
2020 · Antonio Di Meglio, Gwenn Menvielle, et al. · ESMO Open · 25
PDF
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
2024 · Martina Pagliuca, Julie Havas, et al. · JNCI Journal of the National Cancer Institute · 20
852MO REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
2024 · J. Castelli, X. sun, et al. · Annals of Oncology · 9
PDF
Development of Listeriosis during Vancomycin Therapy in a Neutropenic Patient
1996 · Olivier Arsene, Claude Linassier, et al. · Scandinavian Journal of Infectious Diseases · 8
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
2024 · Angeline Ginzac, Ioana Molnar, et al. · Breast Cancer Research and Treatment · 7
PDF
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
2023 · Jens Huober, Patrik Weder, et al. · JAMA Oncology · 7
Perceived discrimination at work: examining social, health and work-related factors as determinants among breast cancer survivors – evidence from the prospective CANTO cohort
2022 · Garazi Ruiz De Azua, Ines Vaz-Luis, et al. · Journal of Epidemiology & Community Health · 7
Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
2022 · Suzette Delaloge, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 2
235P Breast cancer and perceived discrimination in the workplace: A longitudinal cohort study
2020 · G. Ruiz-de-Azua Unzurrunzaga, I.V. Luis, et al. · Annals of Oncology · 2
Too burdened to benefit: job demands and the fading perceived usefulness of health IT
2026 · Olivier Arsene, Claudio Vitari · BMC Health Services Research · 1
Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).
2023 · Martina Pagliuca, Julie Havas, et al. · Journal of Clinical Oncology · 1
Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.
2019 · Antonio Di Meglio, Gwenn Menvielle, et al. · Journal of Clinical Oncology · 1
Conflated Trust, Misread Loyalty: Disentangling Artefact Trust and Provider Trust in Digital Health
2026 · Arsene, Olivier, Vitari, Claudio · HAL
Leveraging the Job Demands-Resources Model to Explore the Effect of Contextual Stressors on Perceived Usefulness of Health Information Technologies
2025 · Arsene, Olivier, Vitari, Claudio · HAL
PDF
Les Logiciels de Santé dans l'exercice des Médecins Libéraux en France : Technostress ou stress Contextuel ?
2024 · Arsene, Olivier, Vitari, Claudio · HAL
PDF
The Role of E-Health Software in Shaping Liberal Physicians' Organizational Routines
2024 · Arsene, Olivier, Vitari, Claudio, et al. · HAL
PDF
Abstract PO4-14-05: Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)
2024 · Antonio Di Meglio, Emilie Thomas, et al. · Cancer Research
Abstract PS02-05: Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
2024 · Youenn Drouet, Emilie Thomas, et al. · Cancer Research
L'effet modérateur de la littératie numérique dans l'adoption des technologies de santé connectées pour le traitement des maladies chroniques
2022 · Arsène, Olivier, Vitari, Claudio · HAL
Works count: 29
Citation count: 1,526
H-index: 9
I10-index: 8
Year
Topic
Type